RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. Anthracyclines are one of the... Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current therapies do not cross the blood-brain barrier.
- Mechanism
- Curator reviewed
RTA 744 is a substance being studied in the treatment of adult brain tumors. RTA 744 crosses the blood-brain barrier and blocks an enzyme needed for cancer growth. RTA 744 is a type of topoisomerase inhibitor. Also called topoisomerase II inhibitor RTA 744.
- Primary indication
- Investigated for use/treatment in brain cancer.Curator reviewed
Resolves to
What you can answer from here — as of September 05, 2026
Which drugs share a target with RTA 744, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account